This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information
AboutDosing & AdministrationDosing & AdministrationDosing in RADosing in PsADosing in UCPractical Considerations

Menu

Close

Efficacy & SafetyClinical Efficacy RARapid Data (ACR20)Head-to-Head Noninferiority Data (ACR50)Biologics DataClinical Efficacy PsAACR20 DataPASI75 DataEnthesitis and Dactylitis DataClinical Efficacy UC8-week EfficacyOnset of Action Data52-week EfficacyOCTAVE Study DesignSafety and TolerabilitySafety in RASafety in PsASafety in UCResources & SupportResources & SupportMaterialsVideosSummary of Prescribing Information

PASI75 Response Rate

PsA patients experienced visible improvements in skin symptoms observed as early as Month 1, and sustained through Year 11-3

   

XELJANZ® (tofacitinib citrate) is not indicated for the treatment of patients with plaque psoriasis4

   

PASI75 was achieved as early as Month 1 and sustained through Year 11-3,*

   

OPAL broaden in csDMARD-IR–treated patients2

   

The OPAL Broaden study was not designed to provide head-to-head comparative efficacy data versus Adalimumab and should not be interpreted as evidence of superiority or noninferiority.2

    

Example

    

Adapted from Mease P, et al. 2017.

    

*Number of patients with >3% of body surface area affected and PASI >0 at baseline were: 82 (XELJANZ® [tofacitinib citrate] 5 mg BID), 82 (placebo), 77 (Adalimumab 40 mg SC Q2W).2
P≤0.05 versus placebo.1,3
P<0.001 versus placebo.1,3
§Statistically significant versus placebo at P≤0.05 as per the prespecified step-down procedure for type I error control within the ACR20 time course.2 PASI75 was defined as a ≥75% improvement from baseline in the PASI score. Patients were included in these analyses if they had >3% of body surface area affected and PASI >0 at baseline.2

    

  • In OPAL Beyond in TNFi-IR–treated patients, there was no significant difference in the proportion of patients achieving a PASI75 response with XELJANZ® (tofacitinib citrate) versus placebo at Month 35
     

  • The PASI75 response rate for XELJANZ® (tofacitinib citrate) 5 mg BID + csDMARD at Month 3 was 21% versus 14% with placebo; P>0.05; not significant1,5

  

OPAL Broaden study design

  

A 12-month, randomised, multicentre, double-blind trial in which 422 patients with PsA who had an inadequate response to at least 1 csDMARD and were TNFi-naïve received either XELJANZ® (tofacitinib citrate) 5 mg BID, XELJANZ® (tofacitinib citrate) 10 mg BID, Adalimumab 40 mg SC Q2W or placebo. At Month 3, all patients randomised to placebo treatment were advanced in a blinded fashion to either XELJANZ® (tofacitinib citrate) 5 mg BID or XELJANZ® (tofacitinib citrate) 10 mg BID. The primary end points were ACR20 response and the change in HAQ-DI at Month 3.2 

  

XELJANZ® (tofacitinib citrate) 5 mg BID is the only approved dosage for the treatment of PsA, and it should not be exceeded. The dosage of 10 mg BID is not licensed for PsA.

  

Explore more

Want to review the improvements in enthesitis and dactylitis with XELJANZ® (tofacitinib citrate)? Learn more Loading

   

   

ACR, American College of Rheumatology; BID, twice daily; csDMARD, conventional synthetic disease-modifying antirheumatic drug; HAQ-DI, Health Assessment Questionnaire-Disability Index; IR, inadequate responder; OPAL, older persons’ assessment and liaison team; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; Q2W, every 2 weeks; SC, subcutaneously; TNFi, tumour necrosis factor inhibitor.

   

References:Xeljanz. Data on file. Pfizer Inc., New York, NY.Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537-1550.Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis (Supplementary Appendix). N Engl J Med. 2017;377(16):1537-7550.Xeljanz. Local product document. Pfizer; 2022. Version LPDTOFA012022.Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525-1536.

   

Please click the Prescribing Information link to view the safety and adverse events information of Xeljanz®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.


PP-XEL-IND-0843 22/07/22

Clinical Efficacy in PsA

About

XELJANZ® (tofacitinib citrate) is a small molecule that selectively targets the JAK pathway

Learn more

Dosing & Administration

   

Helps protect against RA, PsA and UC

Learn more

Resources & Support

Review the upcoming events

Learn more
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-XEL-IND-0843

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

Copyright © 2023 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
For the use only of Registered medical practitioners* or a Hospital or a Laboratory

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.

 

If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-DOL-IND-0251 18 JAN 2023
Yes No
You are now leaving PfizerPro website

​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
PP-DOL-IND-0251 18 JAN 2023